Oragenics Receives Australian Approval for Phase II Concussion Trial
Biotechnology company Oragenics has secured regulatory approval to launch a Phase II clinical trial for ONP-002, a novel intranasal therapy targeting mild traumatic brain injury. The trial represents a potential advancement in treating concussions with a non-invasive approach.
Oragenics Inc., a biotechnology company developing intranasal therapies for brain-related disorders, has received approval from Australia's Human Research Ethics Committee to initiate a Phase II clinical trial for ONP-002, its proprietary neuroprotective treatment for mild traumatic brain injury (mTBI).
The company plans to begin patient enrollment as early as the second quarter of 2025 at Level 1 trauma emergency departments. ONP-002 is a non-invasive intranasal formulation that has demonstrated promising results in preclinical studies, showing potential to reduce inflammation, oxidative stress, and brain swelling associated with concussions.
CEO Janet Huffman highlighted the significance of this regulatory approval, noting it represents a key step in expanding the ONP-002 program internationally. The company is also considering additional enrollment sites in New Zealand, suggesting a broader approach to developing this treatment.
The trial could have significant implications for concussion treatment, offering a potentially groundbreaking non-invasive therapeutic option. Mild traumatic brain injuries are common in sports, military, and civilian contexts, and current treatment options are often limited to rest and symptom management.
Having successfully completed Phase I trials demonstrating safety, Oragenics is positioned to potentially advance a novel approach to treating concussions. The intranasal delivery method could offer advantages over traditional treatment methods, potentially providing faster and more targeted neurological intervention.